Lung cancer survival in Spain and prognostic factors: a prospective, multiregional study.
Lung cancer survival varies greatly from one European country to another. Differences in data collection may account for some of the variations observed. The aim of this work was to ascertain the survival rate in diverse Spanish regions and to analyse the influence of age and other prognostic factors. This was a prospective, observational, multiregional study carried out in 10 hospitals from 8 different Spanish regions. Epidemiological and clinical data, diagnostic and therapeutic procedures, and 3-year survival were recorded according to a common protocol and uniform criteria in 1027 patients with lung cancer diagnosed in 2003. Thirteen (1.26%) were lost to follow-up. The average 3-year survival rate in the remaining 1014 patients was 13.8% with regional rates varying from 6.7% to 19.7%. The resection rate also varied greatly. Early TNM stage, surgical treatment, and asymptomatic status at diagnosis were good independent prognostic factors. Cardiovascular comorbidity and weight loss had an adverse influence on survival. Patients over the age of 70 years were more often asymptomatic at diagnosis; they had less advanced disease and more comorbidity, received less active treatment and had worse survival. The average long-term survival rate in this Spanish series was similar to that reported for other European countries. It varied widely between regions depending on the resection rate. We conclude that although older patients are diagnosed at less advanced stages of disease, they have worse survival because they are less likely to receive effective therapy.
de Cos
Julio Sánchez
JS
Pulmonology Section, Hospital San Pedro de Alcántara, Avenida Pablo Naranjo, s/n, 10001 Cáceres, Extremadura, Spain. jsdce@ya.com
Miravet
Luis
L
Abal
José
J
Núñez
Ana
A
Muñoz
F Javier
FJ
García
Luis
L
Castañar
A M A
AM
Montero
M A C
MA
Hernández
Jesús
J
Alonso
M Angel
MA
D000367:Age Factors; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000628:therapy; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D017678:Sex Distribution; D013030:Spain / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends